Macure Pharma develops and commercializes hospital therapeutics across various medical specialties, addressing unmet medical needs through scientific research. Their portfolio includes niche therapeutics in allergy, cardiology, and oncology, marketed and sold throughout Europe to healthcare providers.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with progressive eye diseases often face challenges accessing specialized diagnostic equipment due to its size and the need for trained personnel. This can lead to delayed diagnosis and suboptimal management of conditions like glaucoma and diabetic retinopathy.
Solution
Macure Pharma is a pharmaceutical company that develops and commercializes hospital therapeutics across various medical specialties. They focus on addressing unmet medical needs through scientific research and the advancement of drug development. The company maintains a robust portfolio of niche hospital therapeutics, which are marketed and sold throughout Europe. Macure Pharma is committed to continuously improving its product offerings and ensuring high-quality standards in its operations.
Target Audience
The primary customers are healthcare providers, including hospitals and clinics, that require specialized therapeutics for patient treatment.
Features
- Portfolio includes hospital therapeutics in allergy, cardiology, and oncology.
- Specific products include Amikacin Macure, Cloxacillin Macure, Deponit® transdermal patches, HTK Solution, Isoprenaline Macure, Lorazepam Macure, Metopocor®, Methylene Blue 1%, Milnocor®, Noradrenalin Macure, Palonosetron Macure, Perlinganit®, and Zyrlex®.
- Active substances for listed products include Amikacinsulfat, Cloxacillin, Glyceryl trinitrate, HTK solution, Isoprenaline, Lorazepam, Metopolol, Methylene Blue, Milrinone, Noradrenaline tratrate, Palonosetron, and Cetrizine HCl.
- Operates across Europe, with product information and regulatory resources available for Denmark, Finland, Norway, Sweden, and the United Kingdom.